All News

pills-384846_640%20%281%29.jpg

Protective Effects of Colchicine in Non-Hospitalized COVID-19

d Jack Cush, MD

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less, randomized, double-blind, placebo-controlled study of 4,488 non-hospitalized patients from Canada, the U.S., Europe, South America and South Africa.

Read Article
FDA%20approved.jpg (keep)

Voclosporin FDA Approved for Lupus Nephritis

d Jack Cush, MD

On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy. FDA approval was based on data from the pivotal AURORA Phase 3 study and the AURA-LV Phase 2 study, which demonstrated the ability of voclosporin to significantly improve LN outcomes after 52 weeks of followup in SLE nephritis patients receiving background standard of care therapies like MMF, and low dose steroids. 

Read Article
podcast logo

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article
NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19 NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. https://t.co/Gdby5qmPNG

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic Week Of 1.17.2021 Myalgias & Arthralgias, Smoking and RA, The Dastardly, nastardly facts of smoking and RA, Oivay the Elevated ESR https://t.co/hTQ46YZTzG

Links:

Dr. John Cush RheumNow ( View Tweet)

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19 https://t.co/DuG7pI4jL9

Links:

Dr. John Cush RheumNow ( View Tweet)

Don’t Hold the Benlysta, Take the Vaccine https://t.co/yBWj2U4ZnZ

Links:

Dr. John Cush RheumNow ( View Tweet)

2 very large UK population studies (millions of pts) show there is no evidence that NSAID use yields harm in those infected with COVID related deaths. There is either no risk (HR 0.96; 0.80, 1.14) or a reduced risk (HR 0.78; 0.64, 0.94) in these studies. https://t.co/gazA83Ogis

Links:

Dr. John Cush RheumNow ( View Tweet)

Osteitis in Systemic Sclerosis is UNCOMMON. French study of 48 pts shows 54% w/ osteitis beneath digital tip ulcers. Pain (75%), erythema (73%), warmth (73%) & 65% had high CRP. X‐ray, CT‐scans or MR. Antibiotics were 1st line therapy. https://t.co/o58gwq2SCC

Links:

Dr. John Cush RheumNow ( View Tweet)

Low Risk of TB with Secukinumab https://t.co/ADdtMNxy2N https://t.co/YTY0eci5Y2

Links:

Dr. John Cush RheumNow ( View Tweet)
Aurinia yesterday announced the FDA that the has approved voclosporin (Lupkynis) for Lupus Nephritis. Voclosporin is an oral calcineurin inhibitor to be used in combination with a background immunosuppressives to treat adultswith active lupus nephritis https://t.co/90ba2Iq0eU

Links:

Dr. John Cush RheumNow ( View Tweet)

Today is the PDUFA date wherein the FDA decides the fate of Aurinias calcineurin inhibitor, Voclosporin, use in lupus nephritis. https://t.co/6du61xGrDq https://t.co/2knPWyNmu4

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID Vaccine Q & A - Dr Kevin Winthrop Dr. Cush interviews Dr. Kevin Winthrop (OHSU) on the use and caveats to COVID-19 vaccination in patients with rheumatic disease and taking biologic and DMARD therapies https://t.co/EJL6hVLnrp https://t.co/XOHk9T04rx

Links:

Dr. John Cush RheumNow ( View Tweet)
MMWR reports 10 cases of anaphylaxis after 4 million doses of Moderna COVID-19 vaccine (2.5 cases per million doses administered). 9/10 occurred within 15 minutes of vaccination. No anaphylaxis-related deaths were reported. https://t.co/lyAVapQH6f

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of Rituximab use in EGPA (Churg-Strauss) found 19 cohort studies, 8 case series, 18 cases, for a total of 368 EGPA patients. RTX yielded 80% w/ complete or partial remission (w/ more complete responses in pANCA+ pts) https://t.co/PTVLSwCHPv https://t.co/PfjBOoi1S7

Links:

Dr. John Cush RheumNow ( View Tweet)
Seronegativity in RA studied using sera and microarrays from 559 RA (283 ACPA-) found 9 autoAbs w/ >90% specificity for seroneg RA. anti-PTX3 & anti-DUSP11 had best performance w/ sensitivity 38% & specificity 88% https://t.co/HraZg7SQPZ https://t.co/6Z8ebvarVm

Links:

Dr. John Cush RheumNow ( View Tweet)
Mortality Risk in Rheumatoid Lung Patients A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks. Read on: https://t.co/RJxDB8tiRu https://t.co/daZppFnteu

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis RCTs of Antidepressants in painful conditions (LBP, sciatica, hip/knee OA) shows SNRIs (Cymbalta, Savella, Effexor etc) have a small & not clinically important for effect on back pain. A clinically important effect on OA cannot be excluded https://t.co/lGqeEHtbnK https://t.co/wcta0VVSqp

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Smoking and RA: The dastardly, nastardly facts of smoking and RA https://t.co/H4jeFIXeGq https://t.co/xWxjzGZWQq

Links:

Dr. John Cush RheumNow ( View Tweet)
In the UK, NICE has recommending ed (to NHS) that filgotinib (Jyseleca) be approved for use in moderate to severe active rheumatoid arthritis (RA).https://t.co/g5zLwIa3MK

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×